Wall Street analyst estimates for Ashland Inc. (ASH): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Ashland Inc. operates as a global supplier of specialized chemicals and additives. Its business activities are structured into four main divisions: Life Sciences; Personal Care & Household; Specialty Additives; and Intermediates and Solvents. The Life Sciences segment delivers pharmaceutical formulations, encompassing controlled release polymers, disintegrants, tablet coatings, thickeners, solubilizers, and binding agents for tablets.
Consensus price target
$77.88 (+4 % vs price $74.68)
between $75.00 and $85.00 · 8 targets published in the last quarter
Closing price, Oct 30
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $1.9B | $1.9B – $1.9B | $3.50 | 6 |
| 2027E | $1.9B | $1.9B – $2.0B | $4.30 | 6 |
Fiscal year ending in September · figures in USD · consensus as of November 1, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 16 |
| Hold | 9 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 25 |
| Avg rating (−2 sell to +2 buy) | 0.64 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-03 | $1.27 | ||
| 2026-07-28 | $1.02 | $0.98 | +3.6% |
| 2026-04-28 | $0.91 | $0.97 | -6.2% |
| 2026-02-02 | $0.26 | $0.23 | +13.0% |
| 2025-11-04 | $1.08 | $1.17 | -7.7% |
| 2025-07-29 | $1.04 | $1.15 | -9.6% |
| 2025-04-30 | $0.99 | $1.10 | -10.0% |
| 2025-01-28 | $0.28 | $0.20 | +40.0% |
Valuation Ratios
| P/E Ratio | 66.09 |
| Price / Book | 1.84 |
| Dividend Yield | 2.24% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.02B | $2.31B | $2.59B | $2.15B | $2.02B | $2.11B | $2.39B | $2.19B | $2.11B | $1.82B |
| Cost of Revenue | $2.13B | $1.58B | $1.73B | $1.50B | $1.42B | $1.44B | $1.56B | $1.52B | $1.50B | $1.27B |
| Gross Profit | $887.0M | $729.0M | $863.0M | $651.0M | $599.0M | $670.0M | $830.0M | $668.0M | $618.0M | $549.0M |
| Research & Development | $87.0M | $83.0M | $73.0M | $58.0M | $56.0M | $50.0M | $55.0M | $51.0M | $55.0M | $54.0M |
| Selling, General & Admin | $858.0M | $610.0M | $599.0M | $426.0M | $400.0M | $358.0M | $393.0M | $365.0M | $404.0M | $345.0M |
| Operating Expenses | $937.0M | $680.0M | $761.0M | $565.0M | $1.06B | $478.0M | $497.0M | $496.0M | $644.0M | $1.32B |
| Operating Income | -$50.0M | $49.0M | $102.0M | $86.0M | -$461.0M | $192.0M | $333.0M | $172.0M | -$26.0M | -$775.0M |
| EBITDA | $180.0M | $453.0M | $404.0M | $382.0M | -$254.0M | $448.0M | $509.0M | $457.0M | $303.0M | -$509.0M |
| Interest Expense | $180.0M | $227.0M | $116.0M | $114.0M | $91.0M | $73.0M | $66.0M | $57.0M | $53.0M | $63.0M |
| Pre-tax Income | -$308.0M | -$196.0M | $11.0M | -$9.0M | -$577.0M | $135.0M | $206.0M | $160.0M | -$24.0M | -$809.0M |
| Income Tax | -$25.0M | -$16.0M | -$8.0M | $30.0M | -$22.0M | -$38.0M | $25.0M | -$8.0M | -$223.0M | $13.0M |
| Net Income | -$29.0M | $1.0M | $114.0M | $505.0M | -$508.0M | $220.0M | $927.0M | $178.0M | $169.0M | -$845.0M |
| EPS | -$0.46 | $0.02 | $1.84 | $8.15 | -$8.33 | $3.66 | $17.17 | $3.36 | $3.45 | -$18.37 |
| EPS (Diluted) | -$0.46 | $0.02 | $1.78 | $8.03 | -$8.39 | $3.66 | $16.41 | $3.31 | $3.38 | -$18.37 |
| Shares Outstanding (Diluted) | 63.0 M | 62.0 M | 64.0 M | 63.0 M | 61.0 M | 61.0 M | 56.0 M | 54.0 M | 50.0 M | 46.0 M |
Price
| Price | $74.68 (closing price, October 30, 2026) |
| Market Cap | $3.4B |
| Exchange | NYSE |
| Country | US |
Related companies: MEOH · WDFC · IOSP · SKE · AVNT · CC · NGVT · KWR
Explore sector: Basic Materials · Chemicals - Specialty
More sections of ASH: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks